AMNEAL PHARMACEUTICALS, INC. Noncash or Part Noncash Acquisition, Payables Assumed
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Noncash or Part Noncash Acquisition, Payables Assumed of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 · last filed 2024-03-14
- AMNEAL PHARMACEUTICALS, INC. noncash or part noncash acquisition, payables assumed for the quarter ending 2021-12-31 was $14.16M.
- AMNEAL PHARMACEUTICALS, INC. noncash or part noncash acquisition, payables assumed for the quarter ending 2020-12-31 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. noncash or part noncash acquisition, payables assumed for fiscal 2023 was $0.00.
- AMNEAL PHARMACEUTICALS, INC. noncash or part noncash acquisition, payables assumed for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- AMNEAL PHARMACEUTICALS, INC. noncash or part noncash acquisition, payables assumed for fiscal 2021 was $14.16M, a 60.70% decline from fiscal 2020.
- AMNEAL PHARMACEUTICALS, INC. noncash or part noncash acquisition, payables assumed for fiscal 2020 was $36.03M.
| Period end | Noncash or Part Noncash Acquisition, Payables Assumed 3 month | Noncash or Part Noncash Acquisition, Payables Assumed 9 month | Noncash or Part Noncash Acquisition, Payables Assumed 12 month |
|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-14 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-03-14 | ||
| 2021-12-31 | $14.16M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $14.16M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-08 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $36.03M 10-K · filed 2023-03-03 | |
| 2020-09-30 | $36.03M 10-Q · filed 2021-11-08 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 | ||
| 2018-12-31 | $0.00 10-K · filed 2020-03-02 | ||
| 2017-12-31 | $14.76M 10-K · filed 2020-03-02 | ||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |